Delivered June quarter results in line with April guidance, with continued strength in diverse revenue streams driving double-digit margins Expect September quarter ...

Vor Bio is licensing global rights to a fusion protein that inhibits two targets to potentially treat the neuromuscular disorder generalized myasthenia gravis. It’s a pivot for Vor, which last ...

Shares of Vor Bio are up 120% in pre-market trade on Thursday. For More Such Health News, visit rttnews.com. The views and opinions expressed herein are the views and opinions of the author and do ...

Less than two months after Vor Bio telegraphed a strategic review, the former cell therapy biotech has made a surprise comeback with a potential $4 billion deal licensing a China-made autoimmune ...

CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it has ...

Today we will run through one way of estimating the intrinsic value of Vor Biopharma Inc. (NASDAQ:VOR) by taking the expected future cash flows and discounting them to today's value. One way to ...

New York is one of the restaurant capitals of the world. East Elmhurst, Queens, could be the next hot spot in fine dining. GOP Calls for Investigation into Federal Card Charges Another week ...

After a three-hour delay that stretched past midnight, passengers finally trudged into a regional jet at LaGuardia Airport for a 90-minute flight earlier this month. However, they wouldn't be ...

A close call at LaGuardia Airport involving two jets has prompted an FAA investigation, highlighting safety concerns in U.S. air travel.